Furthermore, the benefits of a Kv1.3 targeted therapy may not be limited to severe COVID-19, but also extended to “Long Covid” syndrome or post-acute sequelae of SARS-CoV-2 infection (PASC) as it could inhibit the chronic inflammation in the nervous system [Kv1.3 channels regulate microglia function (60, 62)] and pulmonary arteries that are associated with these long-forms of the disease that depend on memory T cells (3). This evidence concerns the gene KCNA3 and COVID-19.